The excellence of the TheraMe! approach has been awarded with a prestigious EXIST grant of the German Ministry of Economy and Energy and is furthermore documented by several high impact publications

The potential of our technology on both, clinical applicability and commercialization has been recognized by the German Ministry of Economy and Energy. In a highly competitive call, our approach has been awarded with an EXIST grant providing approximately 820,000 € for translating our results into marketable products.

In addition, the scientific excellence of our approach is documented by a growing number of peer-reviewed, high impact publications:

Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Molecular Systems Biology (16)e8664: 1-13, 2020

Microfluidics as an Enabling Technology for Personalized Cancer Therapy. Mathur L*, Ballinger M*, Utharala R*, Merten CA. Small. E1904321: 1-18, 2019

A microfluidics platform for combinatorial drug screening on cancer biopsies. Eduati F*, Utharala R*, Madhavan D, Neumann UP, Longerich T, Cramer T, Saez-Rodriguez J, Merten CA. Nature Communications. 9(1):2434: 1-13, 2018